Every material Form 8-K Seaport Therapeutics, Inc. has filed with the SEC since June 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Seaport Therapeutics reported a third-quarter 2026 net loss of $26.4 million, up from $22.5 million a year earlier, as research and development and general and administrative expenses rose. The company had $403.8 million in cash, cash equivalents and investments at September 30, 2026, which it says will fund operations into 2029. The filing reports no revenue, so the loss is the main measure of results for shareholders.
Q3 2026 net loss was $26.4 million, or $0.49 per share, versus $22.5 million, or $9.43 per share, in Q3 2025.
R&D expenses rose to $23.9 million from $20.5 million, mainly due to Phase 2b BUOY-1 trial costs for GlyphAllo.
G&A expenses rose to $6.5 million from $5.0 million, mainly due to costs of operating as a public company.
Cash, cash equivalents and investments totaled $403.8 million at September 30, 2026, versus $233.7 million at December 31, 2025.
Seaport Therapeutics reported second-quarter 2026 results with a net loss of $62.6 million, up from $15.1 million a year earlier. The company said the increase was mainly due to one-time, non-cash stock-based compensation tied to its May IPO, and it ended the quarter with $427.3 million in cash and investments, which it expects to fund operations into 2029.
Net loss was $62.6 million, or $1.78 per share, versus $15.1 million, or $6.40 per share, in Q2 2025.
General and administrative expenses rose to $41.2 million from $5.1 million, including $36.0 million of non-cash stock-based compensation.
Research and development expenses rose to $24.6 million from $13.4 million as GlyphAllo and GlyphAgo advanced into later-stage development.
The IPO raised $260.0 million in gross proceeds, and cash, cash equivalents, and investments totaled $427.3 million as of June 30, 2026.
Seaport Therapeutics reported first-quarter 2026 results showing a net loss of $25.4 million, up from $13.1 million a year earlier, as research and development expenses roughly doubled to $21.4 million. The company had $212.6 million in cash, cash equivalents and investments at March 31, 2026, and said a May 2026 IPO that raised $260.0 million gross should fund operations into 2029, which matters to shareholders because the larger loss and new share issuance both bear on the company's cash runway and per-share results.
Net loss was $25.4 million for Q1 2026 versus $13.1 million for Q1 2025; net loss per share was $10.34 versus $5.65.
R&D expenses were $21.4 million versus $10.5 million, mainly from clinical development of GlyphAllo and GlyphAgo; G&A expenses were $6.1 million versus $5.7 million.
Cash, cash equivalents and investments were $212.6 million at March 31, 2026; the IPO closed in May 2026 with $260.0 million in gross proceeds.
Sharon Mates was appointed to the Board of Directors; Robert Nelson, Eric Elenko and Robert Lyne left the board in connection with the IPO.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Seaport Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →